• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Endocrinology

Steroid implant may improve diabetic macular edema

bySwarup Swaminathan, MDandAndrew Bishara
June 6, 2014
in Endocrinology, Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Both the 0.35mg and 0.7mg dexamethasone dosing led to a significant increase in visual acuity compared to sham.

2. Central retinal thickness, a measure of the extent macular edema, was decreased significantly in the 0.35mg and 0.7mg dexamethasone treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Diabetic macular edema (DME), a common complication of diabetic retinopathy, causes an accumulation of fluid beneath the macula partly due to inflammation. While laser treatment and anti-angiogenic treatments have been utilized, steroid treatments have also been explored. In this study, the authors demonstrated that a sustained-release implant of dexamethasone within the eye can lead to improvement in visual acuity of DME patients lasting up to 3 years. However, the treated patients were more likely to develop cataracts. Limitations of the study include that the trial did not include a treatment arm of the current standard of care. In addition, over 2/3 of the patients had been previously treated; it is unclear how prior treatments may have affected their response to steroids. The increased risk of cataract also must be considered. Nonetheless, the study ultimately demonstrates that steroid therapy may be a valuable option for DME, although their efficacy ought to be compared to current DME therapeutics.

Click to read the study in Ophthalmology

Relevant Reading: Association of Vitreous Inflammatory Factors with Diabetic Macular Edema

In-Depth [randomized controlled trial]: Patients with diagnosed DME (per decreased visual acuity and increased central retinal thickness) were randomly selected to either receive a sham procedure, implant of dexamethasone 0.35mg, or an implant of dexamethasone 0.7mg in this multi-center trial. Patients were regularly followed for 3 years, during which their visual acuity and central retinal thickness was assessed with repeat injections as needed. The primary endpoint was percentage of patients with an improvement of 15 letters in visual acuity. Both the 0.35mg and 0.7mg dexamethasone dosing led to a significant increase in visual acuity compared to sham (18.4%, 22.2%, and 12.0% respectively; p<0.018). Central retinal thickness decreased significantly by 107.9µm and 111.6µm in the 0.35mg and 0.7mg dexamethasone groups compared to the control group (41.9µm; p<0.001). Patients in the treatment arms developed cataract more rapidly, which limited visual acuity but were treated during the study. Overall, steroid treatment of DME appears to be a viable therapy.

RELATED REPORTS

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

More from this author: Argus II retinal prosthesis significantly improves spatial vision in blind patients, Artificial cornea is well retained in patients with ocular surface disease, High prevalence of undiagnosed glaucoma in West Africa, Interferon therapy is superior to methotrexate for uveitis, Rho kinase inhibitor safely reduces intraocular pressure

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: dexamethasonediabetesdiabetic macular edemadiabetic retinopathyOphthalmology
Previous Post

Report argues hospitals may be unconstitutionally forced to accept public for no pay

Next Post

Intraoperative PEEP levels may not affect post-operative pulmonary complications

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post
Hypercortisolemia in ICU patients is due to reduced cortisol metabolism, not increased production

Intraoperative PEEP levels may not affect post-operative pulmonary complications

Report suggests mobile health applications may pose privacy and safety risks

Report suggests mobile health applications may pose privacy and safety risks

Androgen deprivation in prostate cancer: intermittent may compromise survival

Use of 5α-reductase inhibitors may not increase risk of high-grade prostate cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Higher body mass index may be associated with altered vitamin D levels and metabolism
  • #VisualAbstract: Torsemide does not provide additional decrease in mortality compared to furosemide among patients hospitalized for heart failure
  • Community-based adult vision screening program increases access to eye care
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options